Edition:
United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

55.98USD
20 Jan 2017
Change (% chg)

$-0.10 (-0.18%)
Prev Close
$56.08
Open
$56.06
Day's High
$56.32
Day's Low
$55.14
Volume
756,023
Avg. Vol
1,083,549
52-wk High
$61.56
52-wk Low
$27.14

Anstice, David 

Mr. David W. Anstice is Independent Director of Alkermes Plc. From 2006 until his retirement in 2008, Mr. Anstice served as Executive Vice President of Merck, with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Merck's business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck's Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions including President, U.S. Human Health; President, Human Health, the Americas; President, U.S./Canada; and President, Human Health, Europe. He reported to the Merck CEO from 1994 until his retirement in 2008. Mr. Anstice is currently a director of CSL Limited, a global specialty biopharmaceutical company and a board member of the private company NeuClone Pharmaceuticals Pty Ltd., a cell line production company. Mr. Anstice is also Chairman and President of the board for the University of Sydney USA Foundation, Deputy Chairman and a member of the board of the U.S. Studies Centre at the University of Sydney, Australia, a member of the U.S. Advisory Council of the American Australian Association in New York, and an Adjunct Professor at the University of Sydney Business School. Qualifications and Skills: Mr. Anstice's lengthy service with Merck, in combination with the breadth of his responsibilities while at Merck, provides us with experience in, and knowledge of, the global research-based pharmaceutical industry. Mr. Anstice's prior leadership positions in industry organizations, including as a board and executive committee member of BIO for approximately ten years and as Chairman of the National Pharmaceutical Council in 1997, augment his pharmaceutical management, organizational expertise and industry knowledge with knowledge of public policy issues involving pharmaceutical care. Mr. Anstice also has expertise in the areas of strategic planning, risk management and corporate governance.

Basic Compensation

Total Annual Compensation, USD 94,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 370,642
Fiscal Year Total, USD 464,642

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

12,407,500

Shane Cooke

5,087,350

James Frates

3,149,310

Kathryn Biberstein

4,333,980

Elliot Ehrich

4,356,340

Michael Landine

--
As Of  30 Dec 2015